NCT03577743View on ClinicalTrials.gov

Effect of Bevacizumab in Metastatic Triple Negative Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

July 1, 2018

Primary Completion Date

March 15, 2020

Study Completion Date

February 15, 2021

Conditions
Metastatic Triple Negative Breast CancerSafety IssuesEfficacy
Interventions
DRUG

Bevacizumab

-bevacizumab 15m.g/ kg + carboplatin 450m.g + paclitaxel 175m.g/m2 D1 /21 Day until disease progression or un acceptable toxicity .

Trial Locations (1)

Unknown

Clinical Oncology Departement Assuit University Hospital, Asyut

All Listed Sponsors
lead

Assiut University

OTHER

NCT03577743 - Effect of Bevacizumab in Metastatic Triple Negative Breast Cancer | Biotech Hunter | Biotech Hunter